ImageneBio (IMA) CEO Kristin Yarema Receives 153,505 Shares

What Happened Kristin Yarema, CEO of ImageneBio (IMA), reported reclassification/acquisition of 153,505 shares on 2026-07-25. The filing shows two zero-cost entries: 38,376 shares reported under an exercise/conversion code (M) and 115,129 shares reported under an other acquisition code (J). Equivalent derivative entries for the same amounts were simultaneously removed (reported as dispositions of derivative securities at $0), reflecting a reporting change rather than a cash purchase or market sale. Total transaction value shown: $0.

Key Details

• Transaction date: July 25, 2026; Form 4 filed July 28, 2026 (filing appears timely).
• Shares acquired (common stock): 38,376 (M) + 115,129 (J) = 153,505 shares at $0.00 per share.
• Derivative positions removed: matching disposals of 38,376 (M) and 115,129 (J) reported as $0 (derivative).
• Footnotes: RSUs were originally granted July 28, 2025 and previously reported in Table II; the reporting election moves RSUs that settle solely in common stock into Table I. Each RSU equals one share.
• Vesting: 25% of the RSUs vest on the one-year anniversary, then the remaining 75% vests in equal quarterly installments over the next 12 quarters.
• Shares owned after transaction: not specified in the summary data provided in this request.

Context This filing reflects a reporting reclassification of RSUs into common shares rather than a cash purchase or an open-market sale. The entries show no cash exchange (price $0) and do not by themselves signal buying or selling intent. The unvested portion remains subject to the cited vesting schedule.